Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Voyager Therapeutics (VYGR)
NASDAQ:VYGR
Holding VYGR?
Track your performance easily
Earnings Data
Report Date
Mar 11, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.37Last Year’s EPS
1.25Same Quarter Last Year
Strong Buy
Based on 11 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2018
|% Change Since: -25.77%
|Next Earnings Date:Aug 07, 2018
Earnings Call Sentiment|Positive
The call highlighted significant advancements in partnerships, financial stability, and Alzheimer's research. However, challenges in clinical trial outcomes and patient selection were noted. Overall, there is optimism about the potential of their pipeline and strategic partnerships.Company Guidance
During the Q3 2024 earnings call for Voyager Therapeutics, several metrics were highlighted reflecting the company's progress and future guidance. Voyager reported a strong financial position with $345 million in cash at the end of the third quarter, providing a cash runway into 2027. The company has completed enrollment and dosing in the single ascending dose trial for their anti-tau antibody VY7523 for Alzheimer's, with top-line safety and pharmacokinetic data expected in the first half of 2025 and initial tau PET imaging data anticipated in the second half of 2026. The company's pipeline includes four wholly-owned and 14 partnered programs, with partnerships with major companies like Novartis and Neurocrine continuing to expand. Additionally, Voyager's TRACER platform is advancing, with three INDs expected in the following year. Overall, the company is poised for significant value creation with multiple data readouts expected in the next 12 to 24 months.Strong Financial Position
Voyager reported a strong cash position of $345 million at the end of Q3, expected to provide runway into 2027.
Partnerships with Industry Leaders
Voyager established blue-chip partnerships, including Neurocrine, Novartis, and Alexion, with new agreements and development candidates nominated.
Advancement in Alzheimer's Research
Completed enrollment in the single ascending dose trial of VY7523, with expected INDs for three programs next year.
Encouraging Data on Tau Antibody
Voyager's anti-tau antibody VY7523 demonstrated a decrease in pathological tau spread by 70% in preclinical models.
Progress in Tau Silencing Gene Therapy
Ongoing development of a tau silencing gene therapy, on track for U.S. IND and Health Canada CTA filings in 2026.
---
VYGR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
VYGR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $6.83 | $6.69 | -2.05% |
| Aug 06, 2024 | $8.19 | $7.04 | -14.04% |
| May 13, 2024 | $8.48 | $8.48 | 0.00% |
| Feb 28, 2024 | $8.97 | $8.32 | -7.25% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Voyager Therapeutics (VYGR) report earnings?
Voyager Therapeutics (VYGR) is schdueled to report earning on Mar 11, 2025, TBA Not Confirmed.
What is Voyager Therapeutics (VYGR) earnings time?
Voyager Therapeutics (VYGR) earnings time is at Mar 11, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VYGR EPS forecast?
VYGR EPS forecast for the fiscal quarter 2024 (Q4) is -0.37.
---